Bluesight

Bluesight

Bluesight launched in 2012 as Kit Check, named for its original product: an RFID-based medication tray scanning system that automates pharmacy restocking and expiration tracking. Co-founder Kevin MacDonald spotted the opportunity after observing how manual counts and paper logs still dominated hospital pharmacy workflows. The company initially targeted the top 10 health systems by bed count, securing early adopters like Geisinger and the University of Rochester Medical Center. In 2018, the firm acquired Medacist, a controlled substance analytics platform, which became the foundation for its diversion detection software. The combined entity rebranded to Bluesight in 2021, reflecting a broader mission beyond the pharmacy kit. Bluesight's strategy spans three adjacent software modules: RFID-based kit and tray management, controlled substance diversion analytics, and broader pharmacy compliance monitoring. The diversion product uses machine learning to flag anomalous clinician behavior—patients without pain scores receiving opioids, cancelled transactions, tampered vial returns—and provides chain-of-custody documentation for DEA 106 reporting. Confirmed clients include Advocate Aurora Health, Trinity Health, and Yale New Haven Health. The firm participates in direct enterprise sales cycles with hospital networks and health systems, without a disclosed fund structure or co-investment vehicle. Geographic coverage concentrates on the U.S. market. The firm has not disclosed total deployment or headcount. In addition to its Washington, D.C. headquarters, Bluesight maintains an office in the Research Triangle area of North Carolina, a legacy of the Medacist acquisition. In early 2024, the company announced a partnership with Omnicell to integrate diversion analytics into that firm's automated dispensing cabinets, expanding Bluesight's reach to Omnicell's installed base of more than 3,000 hospitals. Bluesight's structural difference lies in its regulatory capture angle: its analytics become the evidentiary record hospitals present to the DEA following a diversion investigation. That posture embeds Bluesight directly into hospital compliance workflows and makes switching costs high. The firm operates as a venture-backed enterprise, having raised minority capital from firms including Baird Capital and Blue Heron Capital, without a family-office, endowment, or sovereign wealth sponsor anchoring the cap table.